JIM CRAMERAging Bull: Cramer's 'Mad Money' Recap (Thursday 4/30/20)By Scott RuttApr 30, 2020 8:43 PM EDT
PRESS RELEASESExelixis Announces Initiation Of CONTACT-03 Phase 3 Pivotal Trial Of Cabozantinib In Combination With Atezolizumab In Previously Treated Metastatic Renal Cell CarcinomaBy Business WireJul 20, 2020 8:00 AM EDT
PRESS RELEASESExelixis Announces Initiation Of CONTACT-02 Phase 3 Pivotal Trial Of Cabozantinib In Combination With Atezolizumab In Previously Treated Metastatic Castration-Resistant Prostate CancerBy Business WireJun 30, 2020 8:00 AM EDT
PRESS RELEASESExelixis To Webcast Virtual Fireside Chat As Part Of The BofA Securities Napa Biopharma Conference On June 24, 2020By Business WireJun 18, 2020 4:05 PM EDT
PRESS RELEASESExelixis Announces Initiation Of CONTACT-01 Phase 3 Pivotal Trial Of Cabozantinib In Combination With Atezolizumab In Previously Treated Metastatic Non-small Cell Lung CancerBy Business WireJun 11, 2020 8:00 AM EDT
PRESS RELEASESExelixis To Webcast Fireside Chats As Part Of Virtual Investor Conferences In JuneBy Business WireJun 3, 2020 4:05 PM EDT
PRESS RELEASESExelixis To Webcast Fireside Chats As Part Of Virtual Investor Conferences In MayBy Business WireMay 6, 2020 4:05 PM EDT
JIM CRAMERAging Bull: Cramer's 'Mad Money' Recap (Thursday 4/30/20)By Scott RuttApr 30, 2020 8:43 PM EDT
PRESS RELEASESExelixis To Release First Quarter 2020 Financial Results On Tuesday, May 5, 2020By Business WireApr 21, 2020 4:05 PM EDT
INVESTINGKidney Cancer Drug From Bristol-Myers and Exelixis Meets Key Phase III EndpointBy Tony OwusuApr 20, 2020 11:03 AM EDT
PRESS RELEASESExelixis To Webcast Virtual Fireside Chat As Part Of The Needham Healthcare Conference On April 15, 2020By Business WireApr 8, 2020 4:05 PM EDT
PRESS RELEASESExelixis Announces Partner Takeda Receives Approval In Japan For CABOMETYX® (cabozantinib) Tablets For The Treatment Of Curatively Unresectable Or Metastatic Renal Cell CarcinomaBy Business WireMar 25, 2020 3:01 AM EDT
PRESS RELEASESExelixis Announces George A. Scangos, Ph.D. To Retire From Its Board Of DirectorsBy Business WireMar 2, 2020 4:05 PM EST
PRESS RELEASESExelixis Announces Webcasts Of Investor Conference Presentations In MarchBy Business WireFeb 26, 2020 4:05 PM EST
PRESS RELEASESExelixis Announces First 100 Patients Enrolled In Phase 3 COSMIC-311 Pivotal Trial Of Cabozantinib In Relapsed Radioiodine-Refractory Differentiated Thyroid CancerBy Business WireFeb 25, 2020 4:06 PM EST
PRESS RELEASESExelixis To Release Fourth Quarter And Full Year 2019 Financial Results On Tuesday, February 25, 2020By Business WireFeb 12, 2020 4:05 PM EST
PRESS RELEASESExelixis Announces Encouraging Results For Cabozantinib In Combination With Atezolizumab In Metastatic Castration-Resistant Prostate CancerBy Business WireFeb 10, 2020 5:00 PM EST
PRESS RELEASESExelixis Announces Webcasts Of Investor Conference Presentations In FebruaryBy Business WireFeb 6, 2020 4:05 PM EST
PRESS RELEASESExelixis Announces Partner Takeda Files New Drug Application In Japan For CABOMETYX® (cabozantinib) For Advanced Hepatocellular CarcinomaBy Business WireJan 29, 2020 2:01 AM EST
PRESS RELEASESExelixis Announces Results For Combination Of Cabozantinib And Nivolumab With Or Without Ipilimumab In Advanced Hepatocellular CarcinomaBy Business WireJan 24, 2020 7:30 AM EST
JIM CRAMERBe Prepared: Cramer's 'Mad Money' Recap (Monday 12/9/19)By Scott RuttDec 9, 2019 8:46 PM EST
JIM CRAMERCan't Keep the Winners Down: Cramer's 'Mad Money' RecapBy Scott RuttMay 9, 2019 8:36 PM EDT
JIM CRAMERCisco Systems, Sunrun, Zebra Technologies: 'Mad Money' Lightning RoundBy Scott RuttMay 9, 2019 8:25 PM EDT
JIM CRAMERFitbit, Moderna, Tilray: 'Mad Money' Lightning RoundBy Bret KenwellFeb 13, 2019 8:45 PM EST
